Drug profile · INN
norethindrone
NOR-QD
norethindrone (NOR-QD) is a progesterone receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral-28. Current US regulatory status: approved.
Drug details — norethindrone
- US status
- approved
- Class
- —
- Route
- ORAL-28
- Patents
- 20
- Programs
- 6
- Data quality
- 0.89
Quick answer
norethindrone (NOR-QD) is a progesterone receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral-28. Current US regulatory status: approved.
Key facts
Mechanism of action
Progesterone receptor agonist
Primary target: Progesterone receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2025207948
CAPSIDES D'AAV POUR LE CIBLAGE DU RÉCEPTEUR DE LA TRANSFERRINE HUMAINE
granted -
WO 2025207932
CAPSIDES DE VAA COMPRENANT DES DOMAINES D'ANTICORPS ANTI-TRANSFERRINE
granted -
WO 2025207959
ANTICORPS ANTI-RÉCEPTEURS DE LA TRANSFERRINE ET LEURS UTILISATIONS
granted -
US 12428487
Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject
granted -
US 12370264
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
granted -
US 12329825
Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject
granted -
US 12325753
Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy
granted -
US 12319743
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
granted -
WO 2025090898
ANTICORPS ANTI-RÉCEPTEUR DE LA TRANSFERRINE ET LEURS UTILISATIONS - RÉFÉRENCES CROISÉES AUX DEMANDES CONNEXES
granted -
US 12263225
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy
granted -
US 12214021
Study on lactoferrin regulation of bone formation by means of vitamin D receptor
granted -
US 12215320
Compositions and methods for gene editing by targeting transferrin
granted -
US 12173078
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
granted -
US 12173079
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
granted -
US 12162948
Methods of engineering transferrin receptor binding polypeptides
granted -
US 12018087
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
granted -
US 12012460
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
granted -
US 11970555
Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
granted -
US 11912778
Methods of engineering transferrin receptor binding polypeptides
granted -
US 11839660
Anti-transferrin receptor antibody and uses thereof
granted
Frequently asked questions
What is norethindrone?
norethindrone (NOR-QD) is a progesterone receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral-28. Current US regulatory status: approved.
What is the brand name for norethindrone?
NOR-QD is a marketed brand name for norethindrone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of norethindrone?
norethindrone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.